Table 1.
Baseline demographic and clinical characteristics of 341 HIV patients with rifampicin and isoniazid-susceptible tuberculosis.
| Total | Eastern Europe N (%) 127 |
Western Europe N (%) 165 |
Latin America N (%) 49 |
P | |
|---|---|---|---|---|---|
| Sex | Male | 98(77.2) | 109 (66.1) | 36 (73.5) | 0.108 |
| Age | Years, median (IQR) | 36.5 (30.9–42.6) | 38.8 (33.0–46.2) | 38.2 (29.2–44.8) | 0.037 |
| Weight | Kg, median (IQR) | 58.0 (50.0–66.0) | 60.0 (54.0–68.0) | 55.0 (45.5–65.5) | 0.225 |
| TB/HIV risk factors | Ever injecting drug use, N (%) | 76 (60.3) | 31 (18.8) | 8 (16.3) | <0.001 |
| History of imprisonment, N (%) | 16 (12.6) | 5 (3.0) | 4 (8.2) | 0.008 | |
| History of excess alcohol consumption, N (%) |
27 (21.3) | 20 (12.1) | 13 (26.5) | 0.026 | |
| Laboratory markers | Haemoglobin (g/dl), median (IQR)a |
11 (9–13) | 11 (9–12) | 11 (10–13) | 0.158 |
| Albumin (g/dl), median (IQR)b | 29 (24–33) | 30 (25–34) | 26 (22–33) | 0.484 | |
| TB disease | Disseminated, N (%) | 64 (50.4) | 95 (57.6) | 29 (59.2) | 0.39 |
| TB treatment | RHZ-based, N (%) | 118 (92.9) | 155 (93.9) | 46 (93.9) | 0.935 |
| RHZ + E, N (%) | 98 (83.1) | 128 (82.6) | 43 (93.5) | 0.181 | |
| RHZ + S, N (%) | 1 (0.8) | 0.426 | |||
| RHZ + ES, N (%) | 10 (8.5) | 3 (1.9) | 1 (2.2) | 0.024 | |
| Hepatitis Cc | Ever, N (%) | 61 (48.0) | 27 (16.4) | 6 (12.2) | <0.001 |
| HIV status | |||||
| Antiretroviral therapy | Yes. N (%) | 21 (16.5) | 64 (38.8) | 19 (38.8) | <0.001 |
| CD4+ cell count, cells/μld | Median (IQR) | 103.5 (35.0–258.0) | 123.0 (35.0–280.0) | 78.0 (28.0–218.0) | 0.31 |
| HIV RNA, log10 copies/mle | Median (IQR) | 5.2 (4.3–5.7) | 5.0 (2.9–5.7) | 4.7 (2.5–5.6) | 0.289 |
Eastern Europe (Belarus, Estonia, Georgia, Latvia, Lithuania, Poland, Romania, Ukraine, Russia); Western Europe (Belgium, Denmark, France, Italy, Spain, Switzerland, United Kingdom); Latin America (Argentina, Chile, and Mexico).
Data for haemoglobin available for 98 (77) patients in EE, 146 (88) in WE, and 41 (84) in LA.
Data for albumin available for 38 (30) patients in EE, 113 (68) in WE, and 26 (53) in LA.
Ever tested positive for hepatitis C antibodies or hepatitis C RNA. Data for hepatitis C available for 91 (72) patients in EE, 121 (73) in WE, and 36 (73) in LA. Missing data are included in the denominator.
Baseline CD4+ cell count was available for 102 (80), 162 (98) and 43 (88) patients in EE, WE, and LA.
Baseline HIV RNA data were available for 68 (54), 157 (95) and 40 (82) patients in EE, WE, and LA.
IQR, interquartile range; R, rifampicin; H, isoniazid; Z, pyrazinamide; E, ethambutol; S, streptomycin.